UBS Group’s VanEck Biotech ETF BBH Stock Holding History

UBS Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3,300	Closed	-$381K	–	8808
2014 Q4	$381K	Buy	+3,300	New	+$372K	﹤0.01%	4433

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

PPWM

Paragon Private Wealth Management Lexington, Kentucky $320M AUM 23.48% 1-Year Est. Return

UBS Group's BBH Position: Q1 2026 in Review

UBS Group reduced its VanEck Biotech ETF (BBH) stake by 18% in Q1 2026, selling an estimated $690K and leaving 16,593 shares worth $3.12M. The position accounts for ﹤0.01% of the portfolio, ranked #4557.

UBS Group first reported a position in BBH in Q4 2014 and has held it in 46 quarters since. The position peaked at $24.4M in Q3 2017. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

UBS Group held 16,593 shares of VanEck Biotech ETF worth $3.12M as of Q1 2026.
UBS Group sold 3,582 VanEck Biotech ETF shares in Q1 2026, an estimated $690K.
VanEck Biotech ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4557 holding.
UBS Group first reported a position in VanEck Biotech ETF in Q4 2014 and has held it in 46 quarters since.
UBS Group's VanEck Biotech ETF position peaked at $24.4M in Q3 2017.
112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.